Executive Scientific Advisor
In 2001 Dr Rob Lambkin-Williams designed and implemented the first Human Viral Challenge Study to be conducted in Europe in the 21st century. He has designed and supervised in excess of 40 studies conducted at Retroscreen Virology since 2001, and has been the Principal Investigator on many. Rob joined Retroscreen Virology in 1995 as a Senior Scientist and is now the Chief Scientific Officer. Rob completed his PhD in Avian Influenza (Bird Flu) at the University of Warwick in 1993 - long before it became a popular news item. He often is the first media point-of-contact regarding Avian Influenza and other virus-related topics. Rob is an expert in respiratory viruses and HIV; he has co-authored many papers including a recent paper in the Nature Medicine journal, which has reset our understanding of the immune response to Influenza, and forms the basis of the RSV’s recent patent application for a universal Influenza vaccine. One of Rob’s key achievements was the establishment of the RSV Human Viral Challenge Model that led to the first proof of concept of a new type of therapeutic agent (known as a siRNA) against an infectious disease. He was the senior author on the paper that described the establishment of the model, which was published in the prestigious American Thoracic Society’s Blue Journal. Other notable achievements include the first study to demonstrate the efficacy of a novel DNA-based vaccine against Influenza, and also a series of studies that dissected the human body’s early response to infection and thus could help develop new highly sensitive diagnostic techniques or antiviral targets.
Antiviral and vaccine drug developmen